Pulmonary Embolism
📧 Sign up to get email alerts when something new happens for Pulmonary Embolism.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-25EMA Authorised: Svariya (previously Rivaroxaban Koanaa) (rivaroxaban) — Koanaa Healthcare GmbH
EMA authorised Svariya (rivaroxaban) for prevention and treatment uses related to thromboembolic conditions; managed by Koanaa Healthcare Gm…
-
EMA approval · 2026-08-18EMA Authorised: Arixtra (fondaparinux sodium) — Viatris Healthcare Limited
The EMA authorised Arixtra (fondaparinux sodium) for venous thrombosis, pulmonary embolism, myocardial infarction, and unstable angina, unde…
-
EMA approval · 2026-01-29EMA Authorised: Arixtra (fondaparinux sodium) — Viatris Healthcare Limited
The EMA authorised Arixtra (fondaparinux sodium) by Viatris Healthcare Limited for thromboembolic conditions including venous thrombosis, pu…
-
EMA approval · 2025-12-17EMA Authorised: Rivaroxaban Koanaa (rivaroxaban) — Koanaa Healthcare GmbH
The European Medicines Agency authorised Koanaa Healthcare GmbH's rivaroxaban product, Koanaa, for indications including venous thromboembol…
-
EMA approval · 2025-11-05EMA Authorised: Rivaroxaban Viatris (previously Rivaroxaban Mylan) (rivaroxaban) — Viatris Limited
The EMA authorised Viatris Limited to market rivaroxaban (brand name Rivaroxaban Viatris), expanding access to this anticoagulant as a gener…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-10-07FDA Approved: RIVAROXABAN — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approves Sun Pharmaceutical's generic rivaroxaban under an original ANDA, for the same indications as the reference product (e.g., reduc…
-
EMA approval · 2025-08-28EMA Authorised: Rivaroxaban Accord (rivaroxaban) — Accord Healthcare S.L.U.
The EMA authorised Accord Healthcare's rivaroxaban product (Rivaroxaban Accord) for multiple indications including acute coronary syndrome, …
-
FDA approval · 2025-06-26FDA Approved: RIVAROXABAN — Original Application (Ascend Laboratories, LLC)
FDA approved Ascend Laboratories' generic rivaroxaban (RIVAROXABAN) under an Original Application, enabling a generic version of the anticoa…
-
FDA approval · 2025-05-15FDA Approved: RIVAROXABAN — Original Application (Aurobindo Pharma Limited)
FDA approved Aurobindo Pharma Limited's original application for generic rivaroxaban, a direct oral anticoagulant.
-
FDA approval · 2025-05-14FDA Approved: RIVAROXABAN — Original Application (XLCare Pharmaceuticals, Inc.)
FDA approved an original application for rivaroxaban (generic) from XLCare Pharmaceuticals, Inc.
-
FDA approval · 2025-05-14FDA Approved: RIVAROXABAN — Original Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' original ANDA for rivaroxaban, making a generic rivaroxaban available in the U.S. for approved indic…
-
FDA approval · 2025-05-14FDA Approved: RIVAROXABAN — Original Application (Dr.Reddy's Laboratories, Inc.)
FDA approved Dr. Reddy's Laboratories' generic rivaroxaban for marketing (ANDA 208534), expanding access to the direct oral anticoagulant. T…
-
FDA approval · 2025-05-14FDA Approved: RIVAROXABAN — Original Application (Macleods Pharmaceuticals Limited)
The FDA approves Macleods Pharmaceuticals Limited's original (ANDA) application for rivaroxaban, a generic version of the anticoagulant.
-
FDA approval · 2025-05-14FDA Approved: RIVAROXABAN — Original Application (Changzhou Pharmaceutical Factory)
FDA approved the original application for rivaroxaban from Changzhou Pharmaceutical Factory under ANDA216995.
-
FDA approval · 2025-03-03FDA Approved: RIVAROXABAN — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved the original application for rivaroxaban from Sun Pharmaceutical Industries, confirming regulatory clearance for a generic riva…
-
FDA approval · 2025-02-24FDA Approved: DABIGATRAN ETEXILATE — Supplemental Application (XLCare Pharmaceuticals, Inc.)
FDA approves a supplemental application for XLCare Pharmaceuticals to market a generic dabigatran etexilate, covering its approved indicatio…
-
FDA approval · 2025-02-03FDA Approved: DABIGATRAN ETEXILATE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved Mylan's original Abbreviated New Drug Application for dabigatran etexilate, enabling a generic version of this anticoagulant to…
-
FDA approval · 2025-01-28FDA Approved: DABIGATRAN ETEXILATE — Original Application (Dr.Reddys Laboratories Inc)
FDA approved Dr.Reddys Laboratories Inc for a generic version of dabigatran etexilate under an Original Application, making the product avai…
-
FDA approval · 2024-12-10FDA Approved: HEPARIN SODIUM — Supplemental Application (Hospira, Inc.)
FDA approved Hospira's supplemental application for Heparin Sodium, updating the product's approval details.
-
FDA approval · 2024-10-24FDA Approved: HEPARIN SODIUM — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved Pfizer's supplemental application for Heparin Sodium, the anticoagulant. The approval updates the product's labeling/indication…
-
EMA approval · 2024-09-12EMA Authorised: Xarelto (rivaroxaban) — Bayer AG
The European Medicines Agency authorised Xarelto (rivaroxaban) for the prevention of venous thromboembolism in patients undergoing arthropla…
-
FDA approval · 2024-09-11FDA Approved: DABIGATRAN ETEXILATE — Original Application (Major Pharmaceuticals)
The FDA approved an original application for dabigatran etexilate (generic) from Major Pharmaceuticals. It covers indications such as nonval…
-
FDA approval · 2024-08-16FDA Approved: DABIGATRAN ETEXILATE — Supplemental Application (Major Pharmaceuticals)
The FDA approved a supplemental application for dabigatran etexilate (generic) submitted by Major Pharmaceuticals.
-
FDA approval · 2024-08-13FDA Approved: DABIGATRAN ETEXILATE — Original Application (XLCare Pharmaceuticals, Inc.)
FDA approved XLCare Pharmaceuticals' original application for dabigatran etexilate (generic), confirming a generic version of the anticoagul…
-
FDA approval · 2024-08-12FDA Approved: DABIGATRAN ETEXILATE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved Alembic Pharmaceuticals' original application for dabigatran etexilate, a generic anticoagulant. It is used to reduce stroke ri…